Skip to main content
. Author manuscript; available in PMC: 2010 Feb 17.
Published in final edited form as: Clin Colorectal Cancer. 2009 Jul;8(3):155. doi: 10.3816/CCC.2009.n.025

Figure 6.

Figure 6

Quantitation of doxorubicin fluorescence intensity (au) in HCT-8 and HT-29 colorectal cancer xenografts (n=4 per treatment group) treated with doxorubicin ± MSC. Pretreatment with MSC showed an improved tumor delivery and penetration of doxorubicin in HCT-8 but not in the HT-29 xenografts, in the combination treatment group.